Bacterial co‐infections with <scp>SARS‐CoV</scp>‐2

DOI Web Site Web Site Web Site Web Site 1 Citations
  • Rasoul Mirzaei
    Department of Microbiology School of Medicine, Hamadan University of Medical Sciences Hamadan Iran
  • Pedram Goodarzi
    Faculty of Pharmacy Iran University of Medical Sciences Tehran Iran
  • Muhammad Asadi
    Faculty of Medicine Iran University of Medical Sciences Tehran Iran
  • Ayda Soltani
    School of Basic Sciences Ale‐Taha Institute of Higher Education Tehran Iran
  • Hussain ali abraham Aljanabi
    Faculty of Medicine Iran University of Medical Sciences Tehran Iran
  • Ali Salimi Jeda
    Department of Virology School of Medicine, Iran University of Medical Sciences Tehran Iran
  • Shirin Dashtbin
    Department of Microbiology School of Medicine, Iran University of Medical Sciences Tehran Iran
  • Saba Jalalifar
    Department of Microbiology School of Medicine, Iran University of Medical Sciences Tehran Iran
  • Rokhsareh Mohammadzadeh
    Department of Microbiology School of Medicine, Iran University of Medical Sciences Tehran Iran
  • Ali Teimoori
    Department of Virology School of Medicine, Hamadan University of Medical Sciences Hamadan Iran
  • Kamran Tari
    Student Research Committee Hamadan University of Medical Sciences Hamadan Iran
  • Mehdi Salari
    Student Research Committee Hamadan University of Medical Sciences Hamadan Iran
  • Sima Ghiasvand
    Department of Microbiology School of Medicine, Hamadan University of Medical Sciences Hamadan Iran
  • Sima Kazemi
    Department of Microbiology School of Medicine, Hamadan University of Medical Sciences Hamadan Iran
  • Rasoul Yousefimashouf
    Department of Microbiology School of Medicine, Hamadan University of Medical Sciences Hamadan Iran
  • Hossein Keyvani
    Department of Virology School of Medicine, Iran University of Medical Sciences Tehran Iran
  • Sajad Karampoor
    Department of Virology School of Medicine, Iran University of Medical Sciences Tehran Iran

Description

<jats:title>Abstract</jats:title><jats:p>The pandemic coronavirus disease 2019 (COVID‐19), caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS‐CoV‐2), has affected millions of people worldwide. To date, there are no proven effective therapies for this virus. Efforts made to develop antiviral strategies for the treatment of COVID‐19 are underway. Respiratory viral infections, such as influenza, predispose patients to co‐infections and these lead to increased disease severity and mortality. Numerous types of antibiotics such as azithromycin have been employed for the prevention and treatment of bacterial co‐infection and secondary bacterial infections in patients with a viral respiratory infection (e.g., SARS‐CoV‐2). Although antibiotics do not directly affect SARS‐CoV‐2, viral respiratory infections often result in bacterial pneumonia. It is possible that some patients die from bacterial co‐infection rather than virus itself. To date, a considerable number of bacterial strains have been resistant to various antibiotics such as azithromycin, and the overuse could render those or other antibiotics even less effective. Therefore, bacterial co‐infection and secondary bacterial infection are considered critical risk factors for the severity and mortality rates of COVID‐19. Also, the antibiotic‐resistant as a result of overusing must be considered. In this review, we will summarize the bacterial co‐infection and secondary bacterial infection in some featured respiratory viral infections, especially COVID‐19.</jats:p>

Journal

  • IUBMB Life

    IUBMB Life 72 (10), 2097-2111, 2020-08-08

    Wiley

Citations (1)*help

See more

Report a problem

Back to top